There are some problems in the supply chain of Chinese pharmaceutical enterprises, such as low operating efficiency, small market scale, large quantity, low concentration and agglomeration rate, and poor communication between enterprises such as information and capital in the supply chain, which makes the pharmaceutical supply chain chaotic for a long time. There are many defects in drug supply management, such as planned procurement, warehousing, drug delivery in pharmacies, and treatment of adverse reactions after taking drugs.
Analysis of the current situation of drug supply chain
1, drug circulation channels are chaotic and difficult to supervise.
China's pharmaceutical distribution channels mainly involve pharmaceutical product manufacturers, wholesalers, retailers and patients. On the surface, there are few participating units, but several different pharmaceutical supply chain models can be changed. Such as drug manufacturers-wholesalers-retailers-patients. Another example is the drug manufacturer-retailer-patient. Some will omit some links. These different channels increase the difficulty of supervision for the regulatory authorities, but also create certain obstacles for the convenience of patients themselves.
2. Supply chain involves many aspects, from raw material suppliers, drug manufacturers to wholesalers, to retailers, and finally to hospitals or pharmacies. On the one hand, the price is not uniform, on the other hand, there are hidden dangers in product supply and quality assurance. 3. The high cost of pharmaceutical supply chain
The cost is very low from the raw materials of drugs entering the production workshop to the drugs being made, but the circulation cost of drugs in the process of reaching patients can account for a large part of the total cost. Although it seems that pharmaceutical manufacturers, wholesalers and retailers at all levels have not suffered any losses, in a hidden sense, patients' resistance to high drug prices indirectly affects the interests of pharmaceutical manufacturers and circulation enterprises at all levels.
Problems existing in the current pharmaceutical supply chain
1, inventory problem In the procurement mode of medical supplies, wholesalers and retailers at all levels decide their own inventory according to their own understanding of the market, and an orderly and efficient inventory mode has not been formed. And due to the lack of effective information sharing, it is difficult to achieve effective allocation of drug resources.
2. Risk issues
Because many wholesalers and retailers are involved, there are differences in transportation conditions and storage equipment between them, so it is difficult to ensure that the same products still maintain the same quality after leaving the factory. As a special commodity related to patients' lives, drugs require high quality. Due to the increasingly difficult supervision, the risk coefficient of drugs before reaching patients has been repeatedly improved.
3. Procurement cost
In multi-level wholesalers, sporadic pharmacies and hospital pharmacies, due to "fragmented" and other reasons, mutual information is not shared, and manufacturers and suppliers need to negotiate and implement necessary procedures in the process of drug procurement, which increases the logistics cost of drugs and thus affects the procurement cost.
4. Doctor-patient problem
As a special kind of consumer goods, drugs often violate the law when they involve economic interests. As the master of professional and technical knowledge, doctors can make use of this advantage to maximize their own interests. Therefore, when prescribing drugs to patients, there are often phenomena such as abusing antibiotics and using expensive substitute drugs, which will cause physical pain and economic losses to patients.
Development trend of pharmaceutical supply chain Under the background of domestic pharmaceutical reform, the future pharmaceutical commercial companies may be distribution companies+information companies+financing companies. Under the new policy and market environment, the clearer the logistics positioning, the faster and more powerful the strategy will be.
1. The concentration and specialization of logistics have been further improved. After the implementation of the "two-vote system", pharmaceutical production enterprises need to directly face provincial or even municipal commercial companies, which makes management more difficult. Production enterprises are more willing to cooperate with powerful group commercial companies, which will lead many small and medium-sized pharmaceutical enterprises to withdraw from the market or join group commercial enterprises, thus greatly improving industry concentration, thus promoting efficient coordination of supply chain and striving for more market share. With the popularization of "two-vote system", circulation enterprises should take the initiative to provide better services and convenience for upstream production enterprises and promote the efficient coordination of supply chain. 2. The national medical policy and the market environment of logistics network operation put forward more requirements for medical logistics, such as the challenge of sales scale expansion to storage capacity; Local drug supervision departments put forward higher requirements for the quality of drug storage and distribution; The zero difference rate between drugs and upstream and downstream terminals will further reduce the profits of pharmaceutical circulation enterprises, forcing enterprises to further improve the efficiency of capital use; More and more peripheral competitors are pouring into the pharmaceutical business, which puts forward higher requirements for the efficiency of drug distribution on the basis of ensuring drug supply. With the change of market and policy, the flattening and multi-warehouse integration of logistics network is the general trend.
3. The functional transformation of pharmaceutical enterprises has gradually changed from relationship maintenance, channel expansion, policy striving, advance payment, collection and logistics distribution to marketing service, pharmaceutical affairs management, health service and logistics professional distribution. The customer-centered service consciousness and concept will be gradually strengthened, and the overall service level of the industry will be significantly improved. For the relatively closed and conservative pharmaceutical circulation industry, although pharmaceutical logistics has its particularity and professionalism, with the gradual improvement of socialized logistics capabilities, pharmaceutical enterprises need to actively integrate into the socialized professional logistics system with a more open, inclusive and inclusive attitude, and use socialized resources to jointly operate. Only in this way can we reduce logistics costs and improve logistics service capabilities. For example, SF tried to build a modern pharmaceutical logistics center in Sichuan and Guangdong by acquiring a GSP qualified enterprise in Sichuan, and entered the pharmaceutical logistics industry.
4. Improvement of logistics automation and modernization At present, except for the logistics network, scale, ability and informatization level of several large pharmaceutical commercial enterprises, the overall logistics situation and ability of the industry are not optimistic, and there is a general lack of understanding and attention to the core competitiveness of logistics. With the impact of decentralization and Internet experience economy, the application level of logistics information technology, especially mobile Internet, big data, cloud computing and other technologies will be greatly improved, and the industry development will fully rely on information technology to realize the visualization, controllability, manageability and traceability of the whole logistics process.